Jordan: These 5 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

DrugPatentWatch^® Estimated Loss of Exclusivity Dates in Jordan

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Summary: Jordan: These 5 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

Subscribe to access the full database, or Start Trial
Tradename	Ingredient	Estimated Entry Opportunity Date
PREPOPIK	citric acid; magnesium oxide; sodium picosulfate	2027-10-12
LASTACAFT	alcaftadine	2026-03-31
KYBELLA	deoxycholic acid	2027-06-19
>Tradename	>Ingredient	>Estimated Entry Opportunity Date

Details: Jordan: These 5 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 12, 2027
Generic Entry Controlled by: Jordan Patent 3,406

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can LASTACAFT (alcaftadine) generic drug versions launch?

Generic name: alcaftadine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 31, 2026
Generic Entry Controlled by: Jordan Patent 3,358

LASTACAFT is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT

See drug price trends for LASTACAFT.

The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch?

Generic name: deoxycholic acid
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: Jordan Patent P20180077

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 19, 2027
Generic Entry Controlled by: Jordan Patent 3,272

KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has ninety patent family members in forty-one countries. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. There are ten drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 01, 2027
Generic Entry Controlled by: Jordan Patent 2,650

OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch?

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 03, 2027
Generic Entry Controlled by: Jordan Patent 3,643

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch?

Generic name: bedaquiline fumarate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 05, 2026
Generic Entry Controlled by: Jordan Patent 2,973

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

This drug has ninety-seven patent family members in thirty-nine countries.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.

When can INQOVI (cedazuridine; decitabine) generic drug versions launch?

Generic name: cedazuridine; decitabine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 16, 2027
Generic Entry Controlled by: Jordan Patent 2,778

INQOVI is a drug marketed by Taiho Oncology. There are six patents protecting this drug.

This drug has ninety-three patent family members in forty-one countries. There has been litigation on patents covering INQOVI

See drug price trends for INQOVI.

The generic ingredient in INQOVI is cedazuridine; decitabine. One supplier is listed for this generic product. Additional details are available on the cedazuridine; decitabine profile page.

When can KERENDIA (finerenone) generic drug versions launch?

Generic name: finerenone
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 27, 2027
Generic Entry Controlled by: Jordan Patent 3,018

KERENDIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug.

This drug has ninety-seven patent family members in forty-nine countries. There has been litigation on patents covering KERENDIA

See drug price trends for KERENDIA.

The generic ingredient in KERENDIA is finerenone. One supplier is listed for this generic product. Additional details are available on the finerenone profile page.